Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Screen Third Party Cell-Culture Technologies; Clarifies Viropro Deal

NEW YORK (GenomeWeb News) — Invitrogen has started a new program to screen technologies from third party companies against its own cell-culture products, the company said today.
Invitrogen also clarified the terms of its recent collaboration with Viropro, which falls under this screening program, saying it would not pay royalties or take commercial interest in any licensing of the technologies.
Invitrogen said it will evaluate GIBCO cell-culture media products and platforms offered by PD-Direct Bioprocess Services along with the outside technologies.
The program is a “unique approach” for evaluating performance of cell-culture products, Jeff Greenberg, vice president of Invitrogen’s BioProduction business, said in a statement.
The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.